Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 494 entries
View as:

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00538343 Org: User:
Start: 10/31/07 End: 01/01/09 Due: 01/01/10

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00618735 Org: User:
Start: 02/29/08 End: 12/31/10 Due: 12/31/11

Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel

Phase: N/A Priority: Normal
NCT ID: NCT03100734 Org: User:
Start: 06/01/17 End: 11/30/18 Due: 11/30/19

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT05767736 Org: User:
Start: 06/08/24 End: 12/01/32 Due: 12/01/33

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT02776072 Org: User:
Start: 05/31/16 End: 12/31/16 Due: 12/31/17

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01051349 Org: User:
Start: 03/31/10 End: 08/25/16 Due: 08/25/17

New Formulation and Food Effect Study of BIIB074

Phase: N/A Priority: Normal
NCT ID: NCT02951221 Org: User:
Start: 12/31/16 End: 02/28/17 Due: 02/28/18

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Phase: N/A Priority: Normal
NCT ID: NCT00744679 Org: User:
Start: 11/30/08 End: 12/31/08 Due: 12/31/09

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

Phase: N/A Priority: Normal
NCT ID: NCT05067790 Org: User:
Start: 01/21/22 End: 06/14/27 Due: 06/14/28

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT00664027 Org: User:
Start: 04/30/08 End: 05/31/09 Due: 05/31/10

Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01549769 Org: User:
Start: 04/30/12 End: 10/31/13 Due: 10/31/14

Safety and PK/PD of RTA 1701 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03579030 Org: User:
Start: 06/20/18 End: 06/28/19 Due: 06/28/20

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03626012 Org: User:
Start: 09/10/18 End: 11/17/21 Due: 11/17/22

A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia

Phase: N/A Priority: Normal
NCT ID: NCT01540630 Org: User:
Start: 03/31/12 End: 06/30/14 Due: 06/30/15

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00031083 Org: User:
Start: 04/02/02 End: 10/10/03 Due: 10/10/04

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00492765 Org: User:
Start: 02/28/06 End: 04/30/10 Due: 04/30/11

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Phase: N/A Priority: Normal
NCT ID: NCT06741657 Org: User:
Start: 01/02/25 End: 10/24/25 Due: 10/24/26

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Phase: N/A Priority: Normal
NCT ID: NCT05658484 Org: User:
Start: 06/09/23 End: 04/12/25 Due: 04/12/26

Functional MRI in Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT01731054 Org: User:
Start: 06/30/13 End: 03/31/15 Due: 03/31/16

Efficacy and Safety of BG00012 in MS

Phase: N/A Priority: Normal
NCT ID: NCT00168701 Org: User:
Start: 10/01/04 End: 03/31/06 Due: 03/31/07

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05152485 Org: User:
Start: 12/15/21 End: 01/31/22 Due: 01/31/23

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT06054893 Org: User:
Start: 07/01/24 End: 02/21/30 Due: 02/21/31

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT05925049 Org: User:
Start: 06/30/23 End: 12/31/25 Due: 12/31/26

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00913666 Org: User:
Start: 11/30/02 End: 11/30/04 Due: 11/30/05

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00078611 Org: User:
Start: 03/31/04 End: 03/31/05 Due: 03/31/06